Optiscan has been featured in Tim Boreham’s Health Check column for Stockhead, which was also syndicated across The Australian and other News Corp mastheads, highlighting the commencement of the company’s new 35-patient head and neck cancer imaging study with Mayo Clinic in Minnesota.

The article notes that the study will evaluate Optiscan’s InVue real-time surgical imaging and InForm digital pathology platforms in an additional cancer type and surgical setting. The study is designed to assess how the technologies perform during head and neck cancer surgery and further explore the role real-time microscopic imaging could play in supporting surgical decision-making and addressing an important area of unmet clinical need.

CEO and Managing Director Dr. Camile Farah said: “Through this study, we’re seeking to better understand how real-time imaging can support surgical decision-making and help address an important unmet clinical need.”

He added: “If the study demonstrates the potential role of real-time imaging during head and neck cancer surgery, it could further demonstrate the tangible impact Vdevice and Fdevice may have in treating a wide range of cancer types.”

Stockhead - Read the full article here.

The Australian - Read the full article here.